Pulmonary Arterial Hypertension Clinical Trial
Official title:
Home-based Exercise Training in Patients With Pulmonary Arterial Hypertension: Effect on Skeletal Muscular Function and Metabolism
Pulmonary Arterial Hypertension has gone from a disease that causes rapid death to a more
chronic condition. Yet, improved survival is associated with major challenges for clinicians
as most patients remain with poor quality of life and limited exercise capacity. The effects
of exercise training on exercise capacity have been largely evaluated and showed an
improvement in 6-minutes walking distance (6MWD), peak V'O2. It is also known that exercise
program improves quality of life. Maximal volitional and nonvolitional strength of the
quadriceps are reduced in patients with Pulmonary Arterial Hypertension and correlated to
exercise capacity. Moreover, on the cellular level, alterations are observed in both the
respiratory as well as the peripheral muscles. Muscle fiber size has been reported to be
decreased in some studies or conversely unaltered in human and animal models. Reduction in
type I fibers and a more anaerobic energy metabolism has also been reported, but not in all
studies. Likewise, a loss in capillary density in quadriceps of patients with Pulmonary
Arterial Hypertension and rats has been reported, but could not be confirmed in other
studies. While the impact of exercise training on clinical outcomes such as exercise capacity
or quality of life is well known, this data highlight the fact that the underlying causes of
peripheral muscle weakness as well as the mechanisms underlying the clinical improvements
observed with exercise programs are not completely understood. Improvement of muscle cell
metabolism in part via the enhancement of oxidative cellular metabolism and decrease in
intracellular lipid accumulation may play a role in improving muscle function and exercise
capacity.
In this study, we intend to evaluate the impact of a 12 weeks home-based rehabilitation
program on peripheral muscle function and metabolism, focusing on lipid infiltration,
oxidative metabolism and epigenetic factors that can be involved in metabolic syndrome, in
patients with Pulmonary Arterial Hypertension.
The 12 weeks home-based rehabilitation program is detailed as follows:
- 1st sessions at the hospital, in the presence of a physiotherapist/kinesiologist
- 3 weeks of supervised home-based rehabilitation (using a telemonitoring system) 3 times
a weeks
- 9 weeks of unsupervised home-based rehabilitation (one phone call a week)
Patients will be evaluated at baseline and at endpoint (12 weeks)
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04076241 -
Effects of Adding Yoga Respiratory Training to Osteopathic Manipulative Treatment in Pulmonary Arterial Hypertension
|
N/A | |
| Completed |
NCT05521113 -
Home-based Pulmonary Rehabilitation With Remote Monitoring in Pulmonary Arterial Hypertension
|
||
| Recruiting |
NCT04972656 -
Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension
|
N/A | |
| Completed |
NCT04908397 -
Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension
|
Phase 1 | |
| Active, not recruiting |
NCT03288025 -
Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)
|
N/A | |
| Completed |
NCT01959815 -
Novel Screening Strategies for Scleroderma PAH
|
||
| Recruiting |
NCT04266197 -
Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study
|
Phase 2 | |
| Active, not recruiting |
NCT06092424 -
High Altitude (HA) Residents With Pulmonary Vascular Diseseases (PVD), Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) vs Sea Level (LA)
|
N/A | |
| Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
| Terminated |
NCT02060487 -
Effects of Oral Sildenafil on Mortality in Adults With PAH
|
Phase 4 | |
| Terminated |
NCT02253394 -
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
|
Phase 4 | |
| Withdrawn |
NCT02958358 -
FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan
|
N/A | |
| Terminated |
NCT01953965 -
Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI.
|
Phase 2 | |
| Not yet recruiting |
NCT01649739 -
Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost
|
Phase 4 | |
| Withdrawn |
NCT01723371 -
Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children
|
Phase 1/Phase 2 | |
| Unknown status |
NCT01712997 -
Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients
|
Phase 3 | |
| Completed |
NCT01548950 -
Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension
|
N/A | |
| Completed |
NCT01165047 -
Nitric Oxide, GeNO Nitrosyl Delivery System
|
Phase 2 | |
| Completed |
NCT00942708 -
Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension
|
Phase 2 | |
| Completed |
NCT00963001 -
Effect of Food on the Pharmacokinetics of Oral Treprostinil
|
Phase 1 |